Gastrointestinal stromal tumors of the stomach: Updates and differences compared to other locations;Gastrointestinale stromatumoren des magens: Neues und besonderes im vergleich zu anderen lokalisationen

Pathologe

Volumn 31, Issue 3, 2010, Pages 195-198

  Wardelmann, E ^a   Hohenberger, P ^b   Reichardt, P ^c   Merkelbach Bruse, S ^a   Schildhaus, H U ^a   Buttner R ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HELIOS Klinikum Bad Saarow   (Germany)

Author keywords

Gastrointestinal stromal tumors (GIST); Imatinib; KIT mutation; PDGFR mutation; Stomach

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ARTICLE; EXON; GASTROINTESTINAL STROMAL TUMOR; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE TUMOR; MUTATION; PATHOLOGY; PROGNOSIS; RECTUM TUMOR; STOMACH MUCOSA; STOMACH TUMOR;

EXONS; GASTRIC MUCOSA; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL NEOPLASMS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECTAL NEOPLASMS; STOMACH NEOPLASMS;

EID: 77953293950     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-009-1270-9     Document Type: Article

References (15)

1. Agaimy A, Wünsch P, Hofstaedter F et al (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31:113-120
2. Kawanowa K, Sakuma Y, Sakurai S et al (2006) High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 37:1527-1535
3. Nilsson B, Bümming P, Meis-Kindblom JM et al (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 103:821-829
4. Pauls K, Merkelbach-Bruse S, Thal D et al (2004) PDGFR- and c-kit mutated gastrointestinal stromal tumors (GIST) are characterized by distinctive histological and immunohistochemical features. Histopathology 46:166-175
5. Lasota J, Dansonka-Mieszkowska A, Sobin L et al (2004) A great majority of GIST with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 84:874-883
6. Lasota J, Stachura J, Miettinen M (2006) GIST with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 86:94-100
7. Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT) - Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269
8. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580 (Pubitemid 28067289)
9. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056
10. Debiec-Rychter M, Sciot R, Le Cesne A et al (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103
11. Corless C, Heinrich M (2008) Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 3:557-586
12. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 23:70-83
13. Fletcher CD, Berman J, Corless CL et al (2002) Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465 (Pubitemid 34747864)
14. Casali P, Jost L, Reichardt P et al (2009) ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:iv64-iv67
15. Fiore M, Palassini E, Fumagalli E et al (2009) Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 35:739-745